Cas no 70849-22-8 (D-Lyxose-1-13C)
D-Lyxose-1-13C Chemical and Physical Properties
Names and Identifiers
-
- D-[1-13C]lyxose
- D-Lyxose-1-13C
- D-[1-(13)C]-lyxose
- HY-128753S3
- CS-0460012
- D-Lyxose-13C-2
- 70849-22-8
- DB-230292
- (2S,3S,4R)-2,3,4,5-tetrahydroxy(113C)pentanal
-
- Inchi: 1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h1,3-5,7-10H,2H2/t3-,4-,5-/m1/s1/i1+1
- InChI Key: PYMYPHUHKUWMLA-IQGOOSNCSA-N
- SMILES: O[C@H]([C@@H]([13CH]=O)O)[C@@H](CO)O
Computed Properties
- Exact Mass: 151.05617825g/mol
- Monoisotopic Mass: 151.05617825g/mol
- Isotope Atom Count: 1
- Hydrogen Bond Donor Count: 4
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 10
- Rotatable Bond Count: 4
- Complexity: 104
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 3
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: -2.3
- Topological Polar Surface Area: 98?2
D-Lyxose-1-13C Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | L501002-5mg |
D-Lyxose-1-13C |
70849-22-8 | 5mg |
$155.00 | 2023-05-18 | ||
| TRC | L501002-50mg |
D-Lyxose-1-13C |
70849-22-8 | 50mg |
$1206.00 | 2023-05-18 | ||
| Omicron Biochemicals | LYX-001-1g |
D-[1-13C]lyxose |
70849-22-8 | 1g |
$730 | 2023-09-21 | ||
| Omicron Biochemicals | LYX-001-0.25g |
D-[1-13C]lyxose |
70849-22-8 | 0.25g |
$305 | 2025-08-06 | ||
| Omicron Biochemicals | LYX-001-0.50g |
D-[1-13C]lyxose |
70849-22-8 | 0.50g |
$525 | 2025-08-06 | ||
| Omicron Biochemicals | LYX-001-1.0g |
D-[1-13C]lyxose |
70849-22-8 | 1.0g |
$895 | 2025-08-06 | ||
| A2B Chem LLC | AH17626-250mg |
D-Lyxose-1-13C |
70849-22-8 | 250mg |
$379.00 | 2024-04-19 | ||
| A2B Chem LLC | AH17626-500mg |
D-Lyxose-1-13C |
70849-22-8 | 500mg |
$614.00 | 2024-04-19 | ||
| A2B Chem LLC | AH17626-1g |
D-Lyxose-1-13C |
70849-22-8 | 1g |
$1003.00 | 2024-04-19 |
D-Lyxose-1-13C Related Literature
-
Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
-
James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
-
Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
-
Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
-
Patricia A. A. M. Vaz,Jo?o Rocha,Artur M. S. Silva New J. Chem., 2016,40, 8198-8201
Additional information on D-Lyxose-1-13C
D-Lyxose-1-13C (CAS No. 70849-22-8): An Essential Compound in Metabolic Studies and Biomedical Research
D-Lyxose-1-13C (CAS No. 70849-22-8) is a labeled sugar that has gained significant attention in the fields of metabolic studies and biomedical research. This compound is a carbon-13 labeled derivative of D-lyxose, a pentose sugar that plays a crucial role in various biological processes. The isotopic labeling of D-Lyxose with 13C at the first carbon position provides researchers with a powerful tool to trace metabolic pathways and understand the dynamics of carbohydrate metabolism.
The use of D-Lyxose-1-13C in metabolic studies has been extensively explored in recent years. One of the key applications of this compound is in the investigation of glycolysis and the pentose phosphate pathway. By incorporating D-Lyxose-1-13C into cells, researchers can track the fate of this sugar through various metabolic pathways, providing insights into how cells utilize and convert carbohydrates. This information is invaluable for understanding the metabolic basis of diseases such as diabetes, cancer, and obesity.
In addition to its role in metabolic studies, D-Lyxose-1-13C has also found applications in the development of diagnostic tools and therapeutic agents. For instance, the labeled sugar can be used in nuclear magnetic resonance (NMR) spectroscopy to monitor the metabolism of cells in real-time. This non-invasive technique allows researchers to observe changes in cellular metabolism under different conditions, such as during drug treatment or exposure to environmental stressors.
The latest research has highlighted the potential of D-Lyxose-1-13C in studying microbial metabolism. Microorganisms play a critical role in various ecological and industrial processes, and understanding their metabolic pathways is essential for optimizing biotechnological applications. By using D-Lyxose-1-13C, researchers can gain detailed insights into how microorganisms process sugars and produce valuable metabolites. This knowledge can be applied to improve fermentation processes, enhance biofuel production, and develop new biocatalysts.
In the context of biomedical research, D-Lyxose-1-13C has been utilized to study the metabolism of cancer cells. Cancer cells often exhibit altered metabolic profiles compared to normal cells, and understanding these differences can lead to the development of more effective therapies. By tracing the fate of D-Lyxose-1-13C in cancer cells, researchers can identify key metabolic pathways that are upregulated or dysregulated in these cells. This information can be used to design targeted therapies that specifically disrupt cancer cell metabolism without affecting healthy cells.
The synthesis and purification of D-Lyxose-1-13C have been optimized to ensure high purity and isotopic enrichment. This ensures that the compound is suitable for use in sensitive analytical techniques such as NMR spectroscopy and mass spectrometry (MS). The high purity and isotopic enrichment also minimize background interference, allowing for more accurate and reliable measurements.
In conclusion, D-Lyxose-1-13C (CAS No. 70849-22-8) is a versatile compound with a wide range of applications in metabolic studies and biomedical research. Its ability to provide detailed insights into carbohydrate metabolism makes it an invaluable tool for researchers working on various biological systems. As new technologies and methodologies continue to emerge, the importance of compounds like D-Lyxose-1-13C will only continue to grow, driving advancements in our understanding of biological processes and the development of new therapeutic strategies.